Protocols - Hemorio

INVESTIGATION OF HEMORRHAGIC SYNDROMES:
PLT TS TTP TAP TT FIB HYPOTHESIS FREQUENCY CONDUCT
Traumatism - Discharge from HEMORIO after 3
Simplex Purpura
confirmations
Vascular Purpura
- Hemorrhage in more than one site
N N N N N N D. V Willebrand
- Remove LES
Def FXIII
Def α2 anti-plasmine
RARE
RARE
- Appointment with the
hematologist, if Hemorrhage in
more than one site
N ↑ ↑ N N N
D. V Willebrand
LES
- Remove LES
- Register
D. V Willebrand - Register
N ↑ N N N N
T. Glanzmann
S. Bernard Soulier
SPD
D. V Willebrand
Hemophilia A / B
- Register, except use of Heparin
N N ↑ N N N
Inhibitor FVIII, FIX and FXI
Lupus anticoagulant
Deficiency of FXI
Use of Heparin
RARE
Use of ACO - Register if remove hepatopathy
N N N ↑ N N Hepatopathy
Deficit of Vit K (II, VII, IX, X)
and vitamin K deficiency
↓ ↑ ↑ ↑ ↑ ↓
CIVD
Hepatopathy
- Dose D-Dimers
- Remove hepatopathy
Deficit Fat via common (II, RARE - Register if remove hepatopathy
V, X)
Hepatopathy
and vitamin K deficiency
N N ↑ ↑ N/↑ N Defic. vit K (II, VII, IX, X)
Lupus Ac
CIVD / Primary Fibrinolisis
Use of ACO or heparin
Use of heparin - Register
N N N N ↑ N
Fibrinogen changes
(Hypo, Dis or
RARE
- Appointment with the
Afibrinogenemia)
hematologist
NOTES:
AT ALL CASES, REMOVE THE USAGE OF DRUGS THAT INTERFERE TO THE HEMOSTASIS.
THE SCREENING IS NOT INCUMBENT TO THE REQUEST OF PLATELET AGGREGATION CURVE,
AT ANY SITUATION.
DISCUSS THE DOUBTFUL CASES TO THE RESPONSIBLE FOR THE SECTOR OF HEMOSTASIS.
VON WILLEBRAND DISEASE
D vW TYPES 1 2 2
2A 2B 2M
TS N / ↑ ↑ ↑ ↑ ↑ ↑
F VIII:c ↓ ↓ / N ↓ / N 5-30 IU/dl 0.05-0.1 IU/dl
FvW:Ag ↓ ↓ ↓ ↓ N ↓ ↓ ↓
FvW:RCo ↓ ↓ ↓ ↓ ↓ ↓ ↓ N ↓ ↓ ↓
RIPA N ↓ ↑ ↓ P ↓ ↓ ↓
FW:Rco/FVW:Ag > 0.7 < 0.7 < 0.7 < 0.7 > 0.7 -
190
2 N
3